UTokyo Repository 東京大学
 

UTokyo Repository >
112 医学系研究科・医学部 >
90 寄付講座 >
1229010 学術雑誌論文 >

このページ(論文)をリンクする場合は次のURLを使用してください: http://hdl.handle.net/2261/72646

タイトル: Cost-Effectiveness of Administering Rituximab for Steroid-Dependent Nephrotic Syndrome and Frequently Relapsing Nephrotic Syndrome : A Preliminary Study in Japan
著者: Takura, Tomoyuki
Takei, Takashi
Nitta, Kosaku
キーワード: Health care economics
Podocytes
発行日: 2017年4月7日
出版者: Nature Publishing Group
掲載誌情報: Tomoyuki Takura, Takashi Takei, Kosaku Nitta, "Cost-Effectiveness of Administering Rituximab for Steroid-Dependent Nephrotic Syndrome and Frequently Relapsing Nephrotic Syndrome: A Preliminary Study in Japan", Scientific Reports Online Edition: 2017/04/07 (Japan time), doi:10.1038/srep46036.
関連URI: http://www.u-tokyo.ac.jp/ja/utokyo-research/research-news/cost-effectiveness-of-new-drug-in-treating-incurable-kidney-disease.html
http://www.u-tokyo.ac.jp/en/utokyo-research/research-news/cost-effectiveness-of-new-drug-in-treating-incurable-kidney-disease.html
http://dx.doi.org/10.1038/srep46036
抄録: With regard to the use of rituximab for patients with steroid-dependent nephrotic syndrome and frequently relapsing nephrotic syndrome, not only has the regimen not been clinically verified but also there is a lack of health economics evidence. Therefore, we conducted a prospective clinical study on 30 patients before (with steroids and immunosuppressants) and after introducing rituximab therapy. Relapse rates and total invoiced medical expenses were selected as the primary endpoints for treatment effectiveness and treatment costs, respectively. As secondary endpoints, cost-effectiveness was compared before and after administering rituximab in relation to previous pharmacotherapy. The observation period was 24 months before and after the initiation of rituximab. We showed that there was a statistically significant improvement in the relapse rate from a mean of 4.30 events before administration to a mean of 0.27 events after administration and that there was a significantly better prognosis in the cumulative avoidance of relapse rate by Kaplan–Meier analysis (p < 0.01). Finally, the total medical costs decreased from 2,923 USD to 1,280 USD per month, and the pre–post cost-effectiveness was confirmed as dominant. We, therefore, conclude that treatment with rituximab was possibly superior to previous pharmacological treatments from a health economics perspective.
内容記述: UTokyo Research掲載「腎臓の難病に対する新しい治療薬の費用対効果」 URI: http://www.u-tokyo.ac.jp/ja/utokyo-research/research-news/cost-effectiveness-of-new-drug-in-treating-incurable-kidney-disease.html
UTokyo Research "Cost-effectiveness of new drug in treating incurable kidney disease" URI: http://www.u-tokyo.ac.jp/en/utokyo-research/research-news/cost-effectiveness-of-new-drug-in-treating-incurable-kidney-disease.html
URI: http://hdl.handle.net/2261/72646
ISSN: 2045-2322
出現カテゴリ:014 自然科学
1229010 学術雑誌論文

この論文のファイル:

ファイル 記述 サイズフォーマット
srep46036.pdf550.25 kBAdobe PDF見る/開く

本リポジトリに保管されているアイテムはすべて著作権により保護されています。

 

Valid XHTML 1.0! DSpace Software Copyright © 2002-2010  Duraspace - ご意見をお寄せください